Mackenzie Financial Corp Bluebird Bio, Inc. Transaction History

Mackenzie Financial Corp

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2018 Feb 06, 2019	SELL	$59.1 - $93.26 $613,458 - $968,038	-10,380 Closed	0 $0
Q3 2018 Nov 15, 2018	BUY	$88.86 - $117.49 $922,366 - $1.22 Million	10,380 New	10,380 $1.52 Million
Q2 2018 Aug 13, 2018	SELL	$99.64 - $127.59 $160,021 - $204,909	-1,606 Closed	0 $0
Q1 2018 May 14, 2018	BUY	$105.8 - $150.94 $169,914 - $242,409	1,606 New	1,606 $274,000

151

63.4M

264K

428K

Ticker BLUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,121,800
Market Cap $29.3M
Description
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...

Get notified when there are updates to the investment portfolio of Mackenzie Financial Corp, based on Form 13F filings with the SEC.

Stay updated on Mackenzie Financial Corp with notifications on news.